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Background: There is increasing epidemiologic evidence that arsenic exposure in utero, even at low
levels found throughout much of the world, is associated with adverse reproductive outcomes and may
contribute to long-term health effects. Animal models, in vitro studies, and human cancer data suggest
that arsenic may induce epigenetic alterations, specifically by altering patterns of DNA methylation.
Objectives: In this study we aimed to identify differences in DNA methylation in cord blood
samples of infants with in utero, low-level arsenic exposure.
Methods: DNA methylation of cord-blood derived DNA from 134 infants involved in a prospective birth cohort in New Hampshire was profiled using the Illumina Infinium Methylation450K
array. In utero arsenic exposure was estimated using maternal urine samples collected at 24–28 weeks
gestation. We used a novel cell mixture deconvolution methodology for examining the association
between inferred white blood cell mixtures in infant cord blood and in utero arsenic exposure; we also
examined the association between methylation at individual CpG loci and arsenic exposure levels.
Results: We found an association between urinary inorganic arsenic concentration and the estimated proportion of CD8+ T lymphocytes (1.18; 95% CI: 0.12, 2.23). Among the top 100 CpG
loci with the lowest p-values based on their association with urinary arsenic levels, there was a statistically significant enrichment of these loci in CpG islands (p = 0.009). Of those in CpG islands
(n = 44), most (75%) exhibited higher methylation levels in the highest exposed group compared
with the lowest exposed group. Also, several CpG loci exhibited a linear dose-dependent relationship between methylation and arsenic exposure.
Conclusions: Our findings suggest that in utero exposure to low levels of arsenic may affect the
epigenome. Long-term follow-up is planned to determine whether the observed changes are associated with health outcomes.
Key words: arsenic, cord blood, DNA methylation, epigenetics, Illumina 450K, in utero arsenic
exposure.
Environ Health Perspect 121:971–977 (2013). http://dx.doi.org/10.1289/ehp.1205925 [Online
11 June 2013]

Introduction
Arsenic, an established environmental toxicant, has been linked to numerous adverse
health outcomes, including cardiovascular disease (Chen et al. 2011; Gong and O’Bryant
2012), cancer (Hopenhayn-Rich et al. 1998),
and skin lesions (Yunus et al. 2011). There is
also a growing concern regarding the effects
of in utero exposure to arsenic on the developing fetus (Vahter 2008). Recent studies have reported that high-level exposure to
arsenic in utero is associated with increased
infant mortality, low birth weight, and birth
defects (Rahman et al. 2009, 2010). Most
previous studies of arsenic exposure and newborn health outcomes, however, have focused
primarily on populations in arsenic-endemic
regions, outside the United States (Vahter
2008). Whereas occupational exposure to
arsenic and contaminated drinking water were
once considered the primary means of arsenic
exposure, dietary intake of arsenic, particularly
from rice consumption, potentially may contribute to the same extent as drinking water in
exposing pregnant women to arsenic (GilbertDiamond et al. 2011). This finding has raised
Environmental Health Perspectives •

volume

concerns regarding the possible health consequences associated with fetal exposure to what
may be relatively common levels of arsenic.
Yet there exists a gap in current knowledge
as to whether findings from populations in
arsenic endemic regions of the world can be
used to infer the risks associated with low-level
arsenic exposure, common to much of the
United States.
Emerging data now suggest that arsenic
may induce epigenetic alterations, specifically by altering patterns of DNA methylation
(Reichard and Puga 2010; Ren et al. 2011).
Differences in global DNA methylation associated with exposure to arsenic have been
reported based on animal (Davis et al. 2000;
Zhao et al. 1997), in vitro (Mass and Wang
1997), and human studies across various tissue
types (i.e., umbilical cord blood and peripheral blood in adult subjects) (Intarasunanont
et al. 2012; Wilhelm et al. 2010). The patterns of DNA methylation alteration associated with arsenic exposure have been far
from consistent, with several studies reporting reductions in global DNA methylation
(Intarasunanont et al. 2012; Wilhelm et al.
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2010; Zhao et al. 1997) and others reporting
evidence of global hypermethylation (Davis
et al. 2000; Mass and Wang 1997). Factors
including the type of markers used for assessment of global methylation, the biological
sample in which DNA methylation was measured, and modifiers such as nutritional folate
levels (Pilsner et al. 2007) may explain the differential findings. In the context of prenatal
exposure to arsenic, two recently published
studies of different Bangladesh cohorts have
reported positive associations between LINE-1
repeat element methylation in cord blood and
arsenic exposure in utero (Kile et al. 2012;
Pilsner et al. 2012), although no significant
associations were observed in a cross-sectional
study conducted in Thailand (Intarasunanont
et al. 2012).
Beyond global methylation alterations,
several recent epidemiologic studies have
reported positive gene-specific associations
between in utero exposure to arsenic and
promoter methylation of CDKN2A (encoding p16INK4A) (Kile et al. 2012) and TP53
(Intarasunanont et al. 2012) measured in
human umbilical cord peripheral blood lymphocytes (PBLs). However, the reported associations of these two studies correspond to
very modest differences in DNA methylation, even though these studies consisted of
individuals residing in the areas of the world
with the highest purported levels of arsenic
exposure. These studies, as well as studies of
adults, have measured DNA methylation in
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unfractioned PBLs, which are relatively easy
to collect and process. However, the primary
limitation is that methylation signatures in
PBLs represent the aggregate methylation
profile of a complex cellular mixture. Thus,
even small changes in percent methylation
may indicate considerable differences in
underlying cell populations, reflecting immunomodulation. Arsenic exposure has been
associated with immune suppression and
impaired macrophage function in exposed
populations (Banerjee et al. 2009; Selgrade
2007). Hence, one possible mechanism for
arsenic-induced diseases in exposed populations is altered immune function related
to alterations of immune cell populations,
which may be evident in blood-based profiles of DNA methylation. Dissecting out the
contributions of different cell types and direct
changes to the methylome on the observed
associations between arsenic exposure and
gene-specific DNA methylation patterns is
critical for understanding the mechanisms of
arsenic’s immunotoxic effects. To address this
limitation, our group has begun to use DNA
methylation signatures of known cell types as
a surrogate for defining cell mixture proportions (Houseman et al. 2012); by applying
this methodology, we are able to interrogate
not only arsenic’s effect on DNA methylation
but also its effect on relative leukocyte subtype proportions.
Despite the collective evidence supporting the role of arsenic exposure on the dys
regulation of DNA methylation, little is known
about potential effects of low levels of arsenic
in utero—common to much of the world’s
population—on DNA methylation. Moreover,
the extent to which such patterns reflect immunomodulation, indicated by shifts in leukocyte
subpopulations, or represent changes in the
underlying methylome, has not been previously
examined. We aimed to address these questions by examining the association between
low-level arsenic exposure at 24–28 weeks
gestation, a period of exposure during which
DNA methylation patterns are becoming
set in hematopoetic stem cells (Rodak et al.
2007), and patterns of e pigenome-wide DNA
methylation in umbilical cord blood samples
from 134 mother–infant pairs enrolled in a
U.S.-based cohort study.

Methods
Study population. The study population
consisted of the 134 initial participants of
the ongoing New Hampshire Birth Cohort
Study (NHBCS), which focuses on pregnant
women from New Hampshire, whose primary household drinking-water source was a
private well (Gilbert-Diamond et al. 2011).
Eligibility criteria included English speaking,
English literate, and mentally competent pregnant women 18–45 years of age. Subjects who
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changed their residence since their last menstrual period or whose home water supply was
from a source other than from a private well
were excluded from the study. Demographic
and lifestyle information was collected during
routine prenatal visits, and for the infant from
the newborn medical chart. This study was
approved by the Committee for the Protection
of Human Subjects at Dartmouth College. All
study participants provided written informed
consent prior to the study.
Arsenic exposure assessment. As previously
described (Gilbert-Diamond et al. 2011), spot
urine samples were collected at approximately
24–28 weeks gestation into acid-washed containers that contained 30 μL of 10 mM diammonium diethyldithiocarbamate to stabilize
arsenic species, and frozen at –80°C until
analysis (within 24 hr of collection). Samples
were analyzed for individual species of urinary arsenic using a high-performance liquid
chromatography inductively coupled plasma
mass spectrometry (ICP-MS) system, and urinary creatinine levels were assessed to control
for urinary dilution. The arsenic speciation
method is capable of quantitatively determining five arsenic species in urine: arsenite
(AsIII), arsenate (AsV), dimethylarsinic acid
(DMAV), monomethylarsonic acid (MMAV),
and arsenobetaine. The separated arsenic species were detected by ICP-MS using timeresolved analysis at m/z 75. The detection
limits ranged from 0.10 to 0.15 μg/L for the
individual arsenic species. Values for samples
with measurements below the limit of detection were taken to be the median between
0 μg/L and the detection limit for that arsenic
species. We calculated total urinary arsenic
concentrations (U-As) by summing inorganic
arsenic (iAs; AsIII and AsV) and the metabolic
products MMAV and DMAV. Arsenobetaine
was excluded from this calculation because it
is thought to be nontoxic and to pass through
the body without being metabolized. We used
total U-As as a measure of in utero exposure
to arsenic because urinary arsenic levels have
been suggested to provide reliable indications of internal dose (Marchiset-Ferlay et al.
2012), and arsenic is known to readily cross
the placenta, leading to fetal serum concentrations similar to maternal levels (Concha
et al. 1998). As a measure of methylation
efficiency, we have also calculated the ratio
of inorganic to total urinary arsenic [iAs/
(iAs + MMAV + DMAV)].
DNA methylation assessment and quality
control. DNA was isolated from cord blood
samples using DNeasy® blood & tissue kits
(Qiagen, Valencia, CA) and bisulfite converted using the EZ DNA Methylation kit
(Zymo, Irvine, CA). Samples were randomized across several plates and subsequently
subjected to epigenome-wide DNA methylation assessment using the Illumina Infinium
volume

HumanMethylation450 BeadChip (Illumina,
San Diego, CA), which simultaneously profiles the methylation status for > 485,000
CpG sites at single-nucleotide resolution.
Microarrays were processed at the Biomedical
Genomics Center at the University of
Minnesota (Minneapolis, MN), following
standard protocols. The methylation status for
each individual CpG locus was calculated as
the ratio of fluorescent signals (β = Max(M,0)/
[Max(M,0) + Max(U,0) + 100]), ranging from
0 (no methylation) to 1 (complete methylation), using the average probe intensity for the
methylated (M) and unmethylated (U) alleles.
The data were assembled using BeadStudio
methylation software (Illumina, San Diego,
CA), without normalization per the manufacturer’s instructions. We used array control
probes to assess the quality of our samples
and evaluate potential problems such as poor
bisulfite conversion or color-specific issues for
each array (Marsit et al. 2009). All CpG loci
on X and Y chromosomes and all loci within
100bp of known single-nucleotide polymorphisms (SNPs) (determined using the annotation for the Illumina HumanMethylation450
array) were excluded from the analysis to
avoid sex-specific methylation bias and biases
related to genetic variability, respectively, leaving 385,249 autosomal CpG loci for analysis in 134 samples. Technical validation of
the methylation array measurements was
obtained using bisulfite pyrosequencing [for
details, see Supplemental Material, Bisulfite
Pyrosequencing (http://dx.doi.org/10.1289/
ehp.1205925)].

Statistical Analysis
Principal components analysis and adjustment
for plate effects. DNA methylation values were
logit [i.e., log(β/1–β)] transformed as in previous studies (Du et al. 2010; Kuan et al. 2010).
To de-convolve the most prevalent sources
of variability in DNA methylation across the
array, we performed a principal components
analysis (PCA) on the resulting methylation
data (Harper et al. 2013; Yang et al. 2010).
PCA represents a feature extraction technique
where the methylation data is orthogonally
transformed, such that the first principal
component has the largest possible variance
(accounts for maximal amount of variability
in the methylation data), and each succeeding
component in turn has the next highest variance possible. The resulting top three principal
components (those representing the maximum
proportion of variability in methylation) were
then examined in terms of their association
with technical aspects concerning the array
(i.e., plate/BeadChip) and patient demographic information using a series of linear
regression models [see Supplemental Material,
Figures S1–S2 and Table S1 (http://dx.doi.
org/10.1289/ehp.1205925)]. Because the
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top three principal components were significantly associated with plate (se Supplemental
Material, Figure S2, Table S1), suggesting
that plate was a major source of variability in
methylation across the array, we adjusted for
plate effects by applying the ComBat method
(Johnson et al. 2007). Following a similar
procedure, we then investigated the resulting plate-adjusted methylation data to ensure
that variation in methylation across the array
induced by plate effects had been successfully attenuated (see Supplemental Material,
Figure S2, Table S2). We also investigated
the top three principal components computed from the plate-adjusted methylation
data in terms of their association with arsenic exposure. Briefly, this was accomplished
by fitting a series of linear regression models
that modeled the principal component as the
dependent variable and quartiles of U-As as
an independent variable, which were adjusted
for maternal age at delivery, infant sex, and
urinary creatinine levels (Barr et al. 2005;
Gamble and Liu 2005). Unless stated otherwise, quartiles of U-As were used as measures
of arsenic exposure because several studies
have reported nonlinear relationships between
arsenic exposure and patterns of DNA methylation at both gene-specific and genome-wide
levels (Chanda et al. 2006; Majumdar et al.
2010) and also to reduce any skewing of the
data by outlying values.
Cell mixture deconvolution analysis.
Using the plate-adjusted methylation data,
we employed a novel statistical methodology
(Houseman et al. 2012) for inferring changes
in the distribution of leukocytes between
quartiles of U-As using DNA methylation
signatures, combined with a previously
obtained external reference data set consisting of methylation signatures from purified
leukocyte samples (Houseman et al. 2012;
Koestler et al. 2012). Further details regarding the reference data set are provided elsewhere (Houseman et al. 2012; Koestler et al.
2012). A critical component of this approach
is the set of DNA methylation signatures of
the major leukocyte components of whole
blood [i.e., B cells, natural killer (NK) cells,
CD8+ T lymphocytes, CD4+ T lymphocytes,
monocytes, and granulocytes]. The methods of Houseman et al. (2012) demonstrate
that the distribution of white blood cells can
be approximated from the DNA methylation measured in whole blood at the top 500
leukocyte differentially methylated regions
(L‑DMRs); application of these methods
allowed us to estimate the expected difference in cell type proportions between U-As
quartiles 2, 3, and 4 and the referent quartile
(quartile 1), as well as the expected change
in cell type proportions based on a 1‑μg/L
increase in the concentration of the individual
arsenic metabolites.
Environmental Health Perspectives •
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In addition, the methods of Houseman
et al. (2012) allowed us to quantify the proportion of total variability in cord blood DNA
methylation explained by estimated immune
cell composition. Consistent with our other
models, we adjusted for maternal age at delivery, infant sex, and urinary creatinine levels.
We note several assumptions regarding the
cell mixture deconvolution method. First, we
assumed that the 500 L‑DMRs—discerned
using the methylation signature from purified
leukocyte subtypes from healthy adults—are
indeed biologically determinant of key differences in cell type across all ages, and therefore
translate to cord-blood. We also assumed that
the methylation status for the 500 L-DMRs
used here is not systematically altered by exposure to arsenic. We note other work (Koestler
et al. 2013) that demonstrates the insensitivity
of the methods to the deletion of some CpGs
(e.g., those that show evidence of serving as
age‑DMRs)—that the accidental inclusion
of some age‑DMRs in the set are unlikely to
influence results. Also, substantial biases due
to arsenic exposure would require systematic alterations of methylation states at the
500 L‑DMRs in a manner consistent with the
linear space spanned by the reference profiles,
an event unlikely unless the alteration was itself
implicated in perturbations of hematopoiesis.
Locus–locus analysis for detecting differentially methylated CpG loci. We implemented a
locus-by-locus analysis aimed toward identifying differentially methylated CpG sites based
on total urinary arsenic levels. Briefly, analysis
of covariance models were fit to each CpG
site separately, and modeled logit-transformed
methylation as the response against quartiles
of total urinary arsenic (quartile 1 treated as
the referent group). Models for U-As were
adjusted for maternal age at delivery, infant
sex, and urinary creatinine levels. Although
our examination was exploratory in nature,
p-values were adjusted for multiple comparisons by computing the Benjamini–Hochberg
adjusted p-values (Benjamini and Hochberg
1995). CpG loci that exhibited a linear dose–
response relationship were identified by fitting a series of linear regression models, which
modeled U-As quartiles as a continuous
covariate; U-As quartiles were assigned values
of 1–4, for quartiles 1–4, respectively.
All analyses were carried out using the
R statistical package, version 2.13 (Vienna,
Austria; www.r-project.org/).

Results
Demographic and clinical information for
the 134 mother–infant pairs is provided in
Table 1. Home tap-water arsenic concentrations ranged from close to the detection
limit (0.03 μg/L) to nearly 100 μg/L, with
22 women (18%) having home drinking water
> 10 μg/L, the current U.S. Environmental
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Protection Agency (EPA) standard (U.S.
EPA 2001). Total U-As, calculated by summing the concentrations of inorganic arsenic,
MMAV, and DMAV, ranged from (0.45 μg/L)
to nearly 300 μg/L, was highly right-skewed
[see Supplemental Material, Figure S3 (http://
dx.doi.org/10.1289/ehp.1205925)], and had
a median concentration of 4.1 μg/L [interquartile range (IQR), 1.8–6.6], which is similar
to the median estimated for the U.S. population as a whole (Caldwell et al. 2009). A single outlying sample with a urinary As value of
nearly 300 μg/L was confirmed. Because of
the skew of the data and this outlier, as well as
the potential nonlinear relationship between
arsenic exposure and DNA methylation, we
examined total urinary arsenic in all analyses as a categorical variable splitting the data
in quartiles.
Supplemental Material, Table S3 (http://
dx.doi.org/10.1289/ehp.1205925) presents coefﬁcient estimates and corresponding
p-values for quartiles of total U-As and their
association with shifts in estimated lymphocyte subsets. Coefficient estimates for each
cell type reflect the estimated percent difference in the proportion of that cell type
between U-As quartiles 2–4 relative to the
lowest quartile (quartile 1). There were no
statistically significant overall differences in
the proportions of cell types among quartiles
Table 1. Demographic, clinical, and phenotypic
information for the study population.
Characteristic
No. of mother–child pairs
Maternal age at delivery (years)
Gestational age (weeks)
Birth weight (kg)
Infant sex
Male
Female
Delivery type
Vaginal
Cesarean section
Unknown
Smoking status
Never
Former
Current
Unknown
School level
Less than 11th grade
High school graduate or equivalent
Junior college graduate or some
college or technical school
College graduate
Postgraduate schooling
Unknown
Maternal urinary As (μg/L)
iAs (μg/L)a
MMAV (μg/L)
DMAV (μg/L)
Tap-water arsenic (μg/L)

Value
134
31 ± 4.6
40 ± 1.3
3.5 ± 0.46
67 (50)
67 (50)
92 (69)
40 (30)
2 (1)
97 (72)
11 (8)
4 (3)
22 (16)
2 (1)
11 (8)
30 (22)
48 (36)
21 (16)
22 (16)
4.1 (1.8–6.6)
0.25 (0.13–0.47)
0.31 (0.15–0.5)
3.4 (1.6–5.7)
1.2 (0.2–6.2)

Values are presented as mean ± SD, n (%), or median
(interquartile range).
aFifty-six samples had measurements below the limit of
detection for iAs.
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of total U-As. Table 2 provides the results of
this model fit to continuous values of total
urinary inorganic As and metabolites individually where the coefficient estimates represent the estimated change in the proportion
of a particular cell type based on a 1-μg/L
increase in the levels of these metabolites. For
iAs/(iAs + MMAV + DMAV), the coefficient
estimates represent the expected difference in
cell type proportions for a 1‑unit increase in
the proportion of inorganic As to total U‑As.
There was a statistically significant positive
association between a 1‑μg/L increase in inorganic arsenic and the proportion of CD8+
T lymphocytes (1.18; 95% CI: 0.12, 2.23)
(Table 2). CD8+ T lymphocytes also were
associated with a 1‑unit increase in the ratio
of inorganic arsenic to total urinary arsenic
(9.11; 95% CI: 0.44, 17.79), but were not
significantly associated with other fractions
(i.e., MMAV and DMAV; Table 2).
Overall, however, white blood cell distributions explained a relatively small proportion of the variability in patterns of cord
blood DNA methylation associated with
in utero exposure to arsenic (3% for total
U-As), so the remaining systematic source of
variation was hypothesized to be alterations
to the methylome itself in some or all of the
cell populations examined. We first used PCA

to reduce the dimensionality of the genomewide DNA methylation data and to investigate the extent to which low-level arsenic
exposure in utero was associated with genomewide variability in cord blood DNA methyla
tion in our population. The results of this
analysis [see Supplemental Material, Table S4
(http://dx.doi.org/10.1289/ehp.1205925)]
revealed no statistically significant association
between U-As quartiles and principal components 1–3, which were estimated to account
for 20%, 12%, and 9% of the variation in
methylation across the array.
To identify individual CpG loci whose
methylation status was associated with exposure, we next examined differential locusspecific patterns of DNA methylation based
on total U-As levels. As shown in Figure 1A,
which depicts –log 10(p-values) (y-axis) for
the association between U-As quartiles and
the methylation of individual CpG loci (the
dependent variable), 68,353 of 385,249 CpG
loci (18%) were significantly associated with
exposure (p < 0.05 for a difference over all
quartiles of U-As), controlling for maternal age at delivery, infant sex, and urinary
c reatinine levels. However no association
was statistically significant after adjusting for
multiple comparisons. Among the 100 CpG
loci with the smallest unadjusted p-values

for the difference in methylation over all
U-As quartiles [see Supplemental Material,
Table S5 (http://dx.doi.org/10.1289/
ehp.1205925)], there was a statistically
significantly greater than expected proportion of loci located in CpG Islands (Fisher’s
exact p = 0.009) (Figure 1B), and of those
in CpG Islands (n = 44), most (75%) exhibited higher methylation levels in the highest exposed group (quartile 4) compared
with the lowest exposed group (quartile 1).
Furthermore, a number of differentially
methylated CpG loci displayed a linear dose–
response relationship across the quartiles of
total U-As levels (see Supplemental Material,
Table S6). Most notably, our analysis identified cg08884395 and cg27514608, associated with genes ESR1 (estrogen receptor 1)
and PPARGC1A (peroxisome proliferator–
activated receptor-γ coactivator 1‑α), respectively (Figure 2), which both exhibited a
negative association between methylation and
arsenic exposure (linear trend p = 0.0009 for
both). Considering the differences in toxicity
of inorganic arsenic, MMA and DMA (Le
et al. 2000), exposure to different forms of
arsenic over the range of U-As concentrations
could potentially confound our results. To
examine the robustness of our results based
on exposure to different forms of arsenic, we

Table 2. Estimated change in the proportions of leukocyte types (95% CI) by continuous specific urinary arsenic exposure measures.
Lymphocytes
CD8+ T
1.18 (0.12, 2.23)*
0.93 (–0.30, 2.15)
0.42 (–0.80, 1.64)
9.11 (0.44, 17.79)*

iAs (per μg/L)
MMAV (per μg/L)
DMAV (per μg/L)
iAs/(iAs + MMAV + DMAV)

CD4+ T
–1.24 (–3.15, 0.68)
–0.24 (–2.62, 2.14)
–0.10 (–2.40, 2.20)
–11.82 (–27.66, 4.02)

Myeloid cells

NK cells
–0.11 (–1.83, 1.62)
–0.48 (–2.59, 1.62)
–0.37 (–2.14, 1.41)
–2.16 (–14.58, 10.27)

B cells
–0.78 (–1.91, 0.36)
–0.68 (–1.88, 0.52)
–0.22 (–1.46, 1.01)
–6.05 (–16.4, 4.27)

Monocytes
–0.37 (–1.31, 0.56)
–0.20 (–1.33, 0.93)
–0.27 (–1.16, 0.62)
–1.81 (–8.20, 4.58)

Granulocytes
1.38 (–2.30, 5.06)
1.15 (0.53, –3.02, 5.32)
0.40 (–3.57, 4.36)
16.91 (–14.12, 47.92)

All four models were controlled for maternal age at delivery, infant sex, and urinary creatinine. Results are based on fitting the cell mixture deconvolution method separately for each
arsenic measure (i.e., iAs, MMAV, etc.). Values are coefficient estimates (95% CIs), where the coefficient estimates represent the estimated change in the proportion of a particular cell
type based on a 1-μg/L increase in the levels of these metabolites. For iAs/(iAs + MMAV + DMAV), the coefficient estimates represent the expected difference in cell type proportions
for a 1-unit increase in the proportion of inorganic As to total U-As.
*p ≤ 0.05.
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Patterns of DNA methylation are established
during embryogenesis and play an important
role in gene transcription, chromosomal stability, X-chromosome inactivation, and tissue differentiation. Alteration of fetal DNA
methylation is a potential mechanism linking
in utero exposures to chronic diseases in adulthood (Kile et al. 2012). The predominantly
rural U.S. study population is distinct from
prior study populations, which were mainly
based outside of the United States and were
typically exposed to greater levels of arsenic
than those of the study population examined
here. However, nearly 20% of this pregnant
population was exposed to household drinking
water above the U.S. EPA standard. Not surprisingly, most women with household drinking water above the U.S. EPA standard were
among those with the highest urinary arsenic
levels (data not shown). This is in line with
our previous report (Gilbert-Diamond et al.
2011) that arsenic exposure from private well
water contributes appreciably to exposure in
this population. Our results, which indicated
some evidence of differential patterns of DNA
methylation across the quartiles of arsenic exposure, support additional investigation into the
biologic effects of this level of arsenic exposure
and provide further evidence for the need of
public health efforts to reduce these exposures.
Animal and in vitro studies have demonstrated effects of arsenic at environmentally
relevant levels (i.e., 10–100 μg/L) on early
immune response (Kozul et al. 2009a, 2009b;
Martin-Chouly et al. 2011; Mattingly et al.
2009), providing a potential biological mechanism for health complications experienced by
prenatally exposed arsenic individuals later
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using DNA methylation profiles as a surrogate measure of leukocyte proportion. The
potential importance of these findings is
underscored by mounting scientific evidence
demonstrating that CD8 + T lymphocytes
contribute to the initiation, progression, and
regulation of several pathogenic autoimmune
responses (Walter and Santamaria 2005),
possibly providing a mechanism by which
in utero exposure to arsenic during relevant
etiologic periods of hematopoiesis results in
an increased risk of autoimmune related illness
later in life (Tseng 2004). It will be critical to
examine prospectively whether the alterations
we have observed are linked to immunological
consequences later in childhood as well as to
validate our findings in additional cohorts.
We further investigated the extent to
which low-level arsenic exposure in utero was
associated with genome-wide DNA methylation variability, assessed using PCA based on
DNA methylation in cord blood. This analysis
revealed no significant associations between
the top three principal components and quartiles of U-As, suggesting that arsenic exposure
may not lead to overt, genome-wide perturbations in DNA methylation to the extent
that had been suggested by studies of “global
methylation” markers. Instead, we found by
examining associations between arsenic and
each CpG loci individually that 18% of the
CpG loci tested were differentially methylated
among quartiles of U-As (p < 0.05). However
none of these associations remained significant
after adjustment for multiple comparisons.
We observed that the top 100 CpGs associated with total urinary arsenic on the basis of
unadjusted p-values were disproportionately
located in CpG islands, and most of these
CpG loci had higher methylation levels in
the highest exposed group (quartile 4) compared with the lowest exposed group (quartile 1). Such findings are in line with existing
reports, which assert that arsenic exposure is
associated with hypermethylation of promoter
region CpG islands (Chen et al. 2001) and the

cg08884395 (ESR1)

cg27514608 (PPARGC1A)

0.85

0.85

Methylation

Discussion

in life. Here we examined whether low-level
arsenic exposure at 24–28 weeks gestation,
a period during which fetal hematopoiesis is
shifting from the liver to the bone marrow
(Rodak et al. 2007), was associated with the
shifts in immune cells. Our results revealed
a statistically significant positive association
between the estimated proportion of CD8+
T lymphocytes and both inorganic arsenic
and the proportion of inorganic arsenic to
total urinary arsenic. Although the methyla
ted species of arsenic also exhibited a positive association with CD8+ T lymphocytes,
unlike inorganic arsenic, the association
between MMA and DMA and CD8+ T lymphocytes did not meet statistical significance
(Table 2). Concentrations of individual
metabolites reflect exposure to inorganic arsenic, direct consumption of methylated forms,
and methylation efficiency (Kile et al. 2009).
Our findings of a stronger association with
inorganic arsenic may be attributable partly
to the varying toxicity of arsenic’s metabolites or epigenetic activity of arsenic’s metabolites. Thus, our results indicate that increased
levels of urinary inorganic arsenic (due to
greater in utero exposure and/or potentially
reduced metabolism of inorganic arsenic to
the methylated species) are associated with
increased proportions of cord-blood CD8 +
T lymphocytes. These results are consistent with recent work in which adult mice
exposed to 100 μg/L of arsenic over 5 weeks
showed increased percentage and total levels
of CD8+ T lymphocytes (Kozul et al. 2009a).
In humans, though, a recent report that evaluated the effects of prenatal arsenic exposure
on thymus function at birth in a Bangledeshi
cohort of 130 mother–infant pairs raised the
possibility that there may be functional deficits
in CD8+ cells associated with arsenic exposure in utero (Ahmed et al. 2012). Although
we recognize that our findings are preliminary, we know of no prior studies reporting
on relationships between arsenic exposure and
cord blood immune cell proportions defined

Methylation

refit models to the CpG sites that exhibited
a dose–response relationship and individually
adjusted for urinary concentrations of inorganic arsenic, MMA, and DMA. These results
(see Supplemental Material, Tables S7–S9)
indicated that adjustment for urinary arsenic
metabolites had very little effect on the association between quartiles of U-As and the DNA
methylation of the dose–response CpG sites,
with all p-values for trend remaining < 0.05.
As validation of the methylation array,
two CpG loci (cg27308738, n=29; and
cg10528424, n=30) were subjected to bisulfite pyrosequencing, because these loci were
among the most variable across the study samples in terms of their methylation levels. Our
results indicated a very high degree of correlation between the methylation array values
and the percent methylation measurements
obtained from pyrosequencing (Pearson’s
correlation coefficient = 0.98 and 0.93 for
cg27308738 and cg10528424, respectively)
[see Supplemental Material, Figure S4 (http://
dx.doi.org/10.1289/ehp.1205925)].
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Figure 2. Crude plots of DNA methylation for cg08884395 (A) and cg27514608 (B) by quartiles of total U-As
for the 134 study subjects. Red lines denote the within-quartile median methylation status.
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well-established role of promoter CpG island
methylation in epigenetic gene control and
disease states (Ferreira et al. 2012; Lorenzen
et al. 2012). Additionally, there were a number of CpG sites that exhibited a linear dose–
response relationship with respect to quartiles
of U-As [see Supplemental Material, Table S6
(http://dx.doi.org/10.1289/ehp.1205925)],
and those relationships remained robust to
individual adjustment for the levels of arsenic’s metabolites (see Supplemental Material,
Tables S7–S9). Although these results require
further validation, they suggest that even
low-level in utero exposure to arsenic may
bring about gene- or CpG-specific epigenetic changes, which themselves may contribute
to altered gene expression and downstream
cellular function.
In addition to purported effects of arsenic as a carcinogen and immunotoxicant, a
growing body of literature is demonstrating
endocrine disruption as an additional mode of
toxicity (Naujokas et al. 2013). We noted in
our analyses that increased levels of total urinary
arsenic were associated with decreased methylation of cg08884395 (linear trend p = 0.0009)
[Figure 2A; see also Supplemental Table S6
(http://dx.doi.org/10.1289/ehp.1205925)],
located in CpG island shore region of ESR1,
encoding estrogen receptor α. Importantly,
methylation of this gene was observed in a
CpG island shore region—regions up to 2 kb
flanking CpG island—which may be the most
enriched with functional CpG sites (Irizarry
et al. 2009). In addition, although not statistically significant after adjustment for multiple
comparisons, our analysis revealed a decrease
in the methylation of cg27514608, for increasing quartiles of U-As (linear trend p = 0.0009)
[Figure 2B; see also Supplemental Table S6
(http://dx.doi.org/10.1289/ehp.1205925)].
This locus is associated with the gene
PPARGC1A, encoding PGC‑1α, a coactivator
of several nuclear receptors including peroxisome proliferator-activated receptors α and γ,
thyroid hormone receptor, mineral corticoid
receptor, and estrogen receptors (Sugawara
et al. 2001). The result with ESR1 is consistent with a report of decreased methylation
and increased expression of ESR1 with in vitro
arsenic exposure in a breast cancer model
(Du et al. 2012), whereas the association with
PPARGC1A is consistent with a report demonstrating up‑regulation of this gene in arsenicinduced Bowen’s disease, a skin carcinoma (Lee
et al. 2011). Given the role of hormone receptors and their pathways in fetal development
and throughout childhood, and the role that
arsenic may be playing in altering these pathways, our data suggest that epigenetic modes of
altered regulation of endocrine pathways may
also be important for future study.
There are notable limitations to the
present study. Our study cohort is largely
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Caucasian, which could limit generalizability. However, our focus on common exposure levels is unique compared with studies
based in arsenic-endemic regions. Although
our study did not directly assess concentrations of arsenic on umbilical cord blood as a
measure of fetal exposure to arsenic, arsenic
is known to readily cross the placenta, leading to fetal serum concentrations similar to
maternal levels (Concha et al. 1998; Hall et al.
2007). Also, the external reference set used in
our cell mixture analysis, which consisted of
DNA methylation signatures from purified
white blood cells, was isolated from different, anonymous, adult, nondiseased individuals’ whole blood (Koestler et al. 2012). As
differences in DNA methylation have been
demonstrated in individuals of varying ages
(Winnefeld and Lyko 2012), the white blood
cell–specific methylation signatures may not
accurately reflect cell-specific patterns of DNA
methylation evident in cord blood, which
consists primarily of infant blood. Further,
our cell mixture analysis used signatures of
DNA methylation as a surrogate for cell mixture composition, whereas a complete assessment of the immune proﬁle would require
ﬂow cytometric measurements. Although
the results from our locus-by-locus analysis
showed some evidence of altered methylation
with arsenic exposure, these results did not
withstand multiple comparison corrections.
Thus, these results need to be replicated in
additional studies. Along the same lines, we
do not have the power to consider differential
effects by sex or other potential modifiers, but
larger studies should consider such effects.

Conclusions
Our novel exploratory examination suggests
that low-level arsenic exposure in utero may
influence the infant epigenome. Particularly,
our findings highlight the possibility that
exposure to arsenic—even at levels common
to much of the world’s population—during
relevant etiologic periods of fetal development
may induce shifts in underlying cell populations, as well as gene-specific alterations in
DNA methylation. Long-term follow-up is
planned to determine whether the observed
changes are associated with short- and longterm health outcomes.
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